Metabonomic analysis of the therapeutic effect of exendin-4 for the treatment of tBHP-induced injury in mouse glomerulus mesangial cells.
Free Radic Res · 2018
Last updated 2026-05-28In a lab study on mouse kidney cells, a GLP-1 drug called exendin-4 reduced cell damage caused by a toxic substance, lowered the percentage of cells dying by apoptosis from 100% to 50%, and restored normal glucose use in damaged cells. The drug also changed how cells processed energy, fats, and proteins compared to untreated damaged cells.
AI summary of the abstract below.
| Journal | Free Radic Res, 2018 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.17 |
| NIH percentile | 11 |
| Molecules | — |
| Conditions studied | Chronic Kidney Disease |
Abstract
Although previous studies have reported the protective effect of glucagon-like peptide-1 (GLP-1) in diabetes nephropathy, the molecular mechanism such as nephroprotection remains elusive. In this study, we explored the molecular mechanism of exendin-4 as an GLP-1 receptor agonist for the treatment of tert-butyl hydroperoxide (t-BHP)-induced injury in mouse glomerulus mesangial cells (SV40 MES 13 cells) via an NMR-based metabonomic analysis. We found that exendin-4 protected mesangial cells from t-BHP-mediated toxicity, decreased the percentage of t-BHP-treated cells undergoing apoptosis, and restored glucose consumption in the t-BHP-treated group. A supervised partial least-squares discriminant analysis (PLS-DA) revealed that the metabolic profiles could be distinguished between the control, t-BHP-treated, and exendin-4-pretreated groups. Our findings indicate that exendin-4 pretreatment can cause distinct changes in energy, glycerol phospholipid, and amino acid metabolism. Our study provides novel insight into the metabolic mechanism of exendin-4-mediated nephroprotective effects.
Verbatim abstract via PubMed 29526117 ↗